Paul McBarron
2023
In 2023, Paul McBarron earned a total compensation of $352.6K as Executive Vice President, Finance, Chief Financial Officer, Chief Operating Officer, Secretary at Cyclacel Pharmaceuticals, a 11% decrease compared to previous year.
Compensation breakdown
| Option Awards | $31,003 |
|---|---|
| Salary | $304,214 |
| Other | $17,398 |
| Total | $352,615 |
McBarron received $304.2K in salary, accounting for 86% of the total pay in 2023.
McBarron also received $31K in option awards and $17.4K in other compensation.
Rankings
In 2023, Paul McBarron's compensation ranked 2,379th out of 2,978 executives tracked by ExecPay. In other words, McBarron earned more than 20.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,379 out of 2,978 | 20th |
Division Manufacturing | 1,337 out of 1,637 | 18th |
Major group Chemicals And Allied Products | 782 out of 906 | 14th |
Industry group Drugs | 763 out of 869 | 12th |
Industry Pharmaceutical Preparations | 549 out of 627 | 12th |
Source: SEC filing on May 7, 2024.
McBarron's colleagues
We found two more compensation records of executives who worked with Paul McBarron at Cyclacel Pharmaceuticals in 2023.
News
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2023 pay slips 13% to $661K
May 7, 2024
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2022 pay falls 43% to $764K
April 28, 2023
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2021 pay slips 5% to $1.3M
April 26, 2022
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2020 pay jumps 39% to $1.4M
April 29, 2021
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2019 pay jumps 35% to $1M
May 12, 2020